



## **Collegium to Present at Upcoming Investor Conferences**

March 16, 2018

CANTON, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in March:

- The Oppenheimer & Company 28<sup>th</sup> Annual Healthcare Conference on Wednesday, March 21<sup>st</sup> at 9:10 a.m. ET in New York City
- The Needham 17<sup>th</sup> Annual Healthcare Conference on Wednesday, March 28<sup>th</sup> at 10:30 a.m. ET in New York City

### **About Collegium Pharmaceutical, Inc.**

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.

### **About Xtampza ER**

Xtampza® ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:

Alex Dasalla

[adasalla@collegiumpharma.com](mailto:adasalla@collegiumpharma.com)



Source: Collegium Pharmaceutical, Inc.